Across TCGA pan-cancer cohorts, TEX261 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TEX261 data layer compared with 27 for mass-spec protein.
The strongest signal is observed in cholangiocarcinoma (CHOL), where higher TEX261 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TEX261 expression acts as an unfavorable survival marker.
CHOL are the cancer types where TEX261 Mutation most reproducibly stratifies survival.